Nicolas Jonckheere
Overview
Explore the profile of Nicolas Jonckheere including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1046
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kasprowicz A, Cavdarli S, Delannoy P, Le Guezennec X, Defebvre C, Spriet C, et al.
Mol Cell Biochem
. 2024 Oct;
PMID: 39395135
O-acetylated GD2 (OAcGD2) is a cancer-related antigen that is currently being explored for therapeutic use. Exploring the intricate mechanisms behind OAcGD2 synthesis in cancer cells has long been a challenge....
2.
Du Q, Yu Z, Zhang Z, Yang J, Jonckheere N, Shi S, et al.
J Gastrointest Oncol
. 2024 Jul;
15(3):1179-1197.
PMID: 38989416
Background: Pancreatic adenocarcinoma (PAAD) is referred to as an immunologically "cold" tumor that responds poorly to immunotherapy. A fundamental theory that explains the low immunogenicity of PAAD is the dramatically...
3.
Quilbe A, Mustapha R, Duchene B, Kumar A, Werkmeister E, Leteurtre E, et al.
Front Immunol
. 2023 Dec;
14:1267279.
PMID: 38098486
Background: Pancreatic adenocarcinoma (PDAC) is a devastating disease with an urgent need for therapeutic innovation. Immune checkpoint inhibition has shown promise in a variety of solid tumors, but most clinical...
4.
Jannin A, Dessein A, Do Cao C, Vantyghem M, Chevalier B, Van Seuningen I, et al.
Front Endocrinol (Lausanne)
. 2023 Nov;
14:1248575.
PMID: 37908747
Introduction: Reprogramming of cellular metabolism is now a hallmark of tumorigenesis. In recent years, research on pancreatic neuroendocrine tumors (pNETs) has focused on genetic and epigenetic modifications and related signaling...
5.
Auwercx J, Kischel P, Lefebvre T, Jonckheere N, Vanlaeys A, Guenin S, et al.
Cells
. 2022 Jul;
11(14).
PMID: 35883700
Pancreatic diseases, such as pancreatitis or pancreatic ductal adenocarcinoma, are characterized by the presence of activated pancreatic stellate cells (PSCs). These cells represent key actors in the tumor stroma, as...
6.
Foulon A, Rybarczyk P, Jonckheere N, Brabencova E, Sevestre H, Ouadid-Ahidouch H, et al.
Int J Mol Sci
. 2022 Mar;
23(6).
PMID: 35328381
Breast cancer is the leading cause of cancer death among women in worldwide and France. The disease prognosis and treatment differ from one breast cancer subtype to another, and the...
7.
Raab S, Very N, Duchene B, Rybarczyk P, Jonckheere N, El Yazidi-Belkoura I, et al.
Oncol Lett
. 2022 Mar;
23(4):105.
PMID: 35242233
Tumor occurrence and development are closely related to metabolism abnormalities. One of the metabolic networks that is dysregulated during carcinogenesis is the fatty acid synthesis pathway, which is mainly controlled...
8.
Boukrout N, Souidi M, Lahdaoui F, Duchene B, Neve B, Coppin L, et al.
Cancers (Basel)
. 2021 Dec;
13(24).
PMID: 34944818
Background: Pancreatic adenocarcinoma (PDAC) is a deadly cancer with an extremely poor prognosis. MUC4 membrane-bound mucin is neoexpressed in early pancreatic neoplastic lesions and is associated with PDAC progression and...
9.
Stoup N, Liberelle M, Schulz C, Cavdarli S, Vasseur R, Magnez R, et al.
Cancers (Basel)
. 2021 Nov;
13(22).
PMID: 34830899
The HER2 receptor and its MUC4 mucin partner form an oncogenic complex via an extracellular region of MUC4 encompassing three EGF domains that promotes tumor progression of pancreatic cancer (PC)...
10.
Hadj Bachir E, Poiraud C, Paget S, Stoup N, El Moghrabi S, Duchene B, et al.
Biol Cell
. 2021 Sep;
114(1):32-55.
PMID: 34561874
Background Information: Although improvements have been made in the management of pancreatic adenocarcinoma (PDAC) during the past 20 years, the prognosis of this deadly disease remains poor with an overall...